# US 2003/0203471 A1 · Bacterial small-molecule three-hybrid system

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0203471 A1
- Document ID: US20030203471A1
- Status: Published application
- Kind: A1
- Application number: 10/132,039
- Filed: 2002-04-24
- Published: 2003-10-30
- Earliest claimed: 2002-04-24
- Assignees: The Trustees of Columbia University in the City of New York
- Inventors: Eric A. Althoff; Virginia W. Cornish
- Web page: https://patentgrep.com/patent/US20030203471A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/47: from mammals
- C07K 14/4705: {stimulating, promoting or activating activity}
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A transgenic bacterial cell comprising (a) a dimeric small molecule which comprises a first moiety known to bind a first receptor domain covalently linked to a second moiety known to bind a second receptor domain; (b) nucleotide sequences which upon transcription encode i) a first fusion protein comprising the first receptor domain, and ii) a second fusion protein comprising the second receptor domain; and (c) a reporter gene wherein expression of the reporter gene is conditioned on the proximity of the first fusion protein to the second fusion protein. The cell is also adapted for use in a method for identifying a molecule that binds to a known target in a bacterial cell from a pool of candidate molecules, and a method for identifying an unknown target receptor to which a molecule is capable of binding in a bacterial cell. Also described are compounds and kits for carrying out the methods.

## Claims

### Claim 1

A transgenic bacterial cell comprising
(a) a dimeric small molecule which comprises a first moiety known to bind a first receptor domain covalently linked to a second moiety capable of binding a second receptor domain, wherein the first and second moieties are different;
(b) nucleotide sequences which upon transcription encode
i) a first fusion protein comprising the first receptor domain, and
ii) a second fusion protein comprising the second receptor domain; and
(c) a reporter gene wherein expression of the reporter gene is conditioned on the proximity of the first fusion protein to the second fusion protein.

### Claim 2 (depends on 1)

The bacterial cell of claim 1, wherein the dimeric small molecule has the formula:
H1-Y—H2
wherein each of H1 and H2 may be the same or different and capable of binding to a receptor which is the same or different with a IC50 of less than 100 μM; and
wherein Y is a linker which may be present or absent.

### Claim 3 (depends on 2)

The bacterial cell of claim 2, wherein H1 or H2 is capable of binding to a receptor with a IC50 of less than 10 μM.

### Claim 4 (depends on 2)

The bacterial cell of claim 2, wherein H1 or H2 is capable of binding to a receptor with a IC50 of less than 1 μM.

### Claim 5 (depends on 2)

The bacterial cell of claim 2, wherein H1 or H2 is capable of binding to a receptor with a IC50 of less than 100 nM.

### Claim 6 (depends on 2)

The bacterial cell of claim 2, wherein H1 or H2 is capable of binding to a receptor with a IC50 of less than 10 nM.

### Claim 7 (depends on 2)

The bacterial cell of claim 2, wherein H1 or H2 is capable of binding to a receptor with a IC50 of less than 1 nM.

### Claim 8 (depends on 2)

The bacterial cell of claim 2, wherein H1 or H2 is a methotrexate moiety, FK506 moiety, an FK506 analog, a tetracycline moiety, or a cephem moiety.

### Claim 9 (depends on 8)

The bacterial cell of claim 8, wherein H1 or H2 is a methotrexate moiety.

### Claim 10 (depends on 8)

The bacterial cell of claim 8, wherein H1 or H2 is an FK506 analog.

### Claim 11 (depends on 10)

The bacterial cell of claim 10, wherein the FK506 analog has the structure:
9

### Claim 12 (depends on 2)

The bacterial cell of claim 2, wherein the dimeric small molecule has the structure:
10
wherein n is an integer from 1 to 20.

### Claim 13 (depends on 12)

The bacterial cell of claim 12, wherein n is an integer from 2 to 12.

### Claim 14 (depends on 12)

The bacterial cell of claim 12, wherein n is an integer from 3 to 9.

### Claim 15 (depends on 12)

The bacterial cell of claim 12, wherein n is 8.

### Claim 16 (depends on 1)

The bacterial cell of claim 1, wherein the first fusion protein further comprises a DNA binding domain, and the second fusion protein further comprises a transcription activation domain.

### Claim 17 (depends on 1)

The bacterial cell of claim 1, wherein the first fusion protein further comprises a transcription activation domain, and the second fusion protein further comprises a DNA binding domain.

### Claim 18 (depends on 16, 17)

The bacterial cell of claim 16 or 17, wherein the transcription activation domain is αNTD.

### Claim 19 (depends on 16, 17)

The bacterial cell of claim 16 or 17, wherein the DNA-binding domain is λcI, AraC, LexA, Gal4, or zinc fingers.

### Claim 20 (depends on 1)

The bacterial cell of claim 1, wherein the first or the second receptor domain is that of dihydrofolate reductase (“DHFR”), glucocorticoid receptor, FKBP12, FKBP mutants, tetracycline repressor, or a penicillin binding protein.

### Claim 21 (depends on 20)

The bacterial cell of claim 20, wherein the DHFR is the E. coli DHFR (“eDHFR”).

### Claim 22 (depends on 1)

The bacterial cell of claim 1, wherein the first fusion protein is DHFR-λcI or FKBP12-λcI.

### Claim 23 (depends on 1)

The bacterial cell of claim 1, wherein the second fusion protein is DHFR-αNTD or FKBP12-αNTD.

### Claim 24 (depends on 1)

The bacterial cell of claim 1, wherein the reporter gene is Lac Z, araBAD, aadA (spectinomycin resistance), his3, β-lactamase, GFP, luciferase, TetR (tetracyclin resistance), KanR (kanamycin resistance), Cm (chloramphenicol resistance).

### Claim 25 (depends on 24)

The bacterial cell of claim 24, wherein the reporter gene is Lac Z.

### Claim 26

A transgenic bacterial cell comprising
(a) a dimeric small molecule which comprises a methotrexate moiety covalently linked to a moiety capable of binding a receptor domain;
(b) nucleotide sequences which upon transcription encode
i) a first fusion protein comprising a DHFR domain, and
ii) a second fusion protein comprising the receptor domain; and
(c) a reporter gene wherein expression of the reporter gene is conditioned on the proximity of the first fusion protein to the second fusion protein.

### Claim 27 (depends on 26)

The bacterial cell of claim 26 wherein the moiety known to bind a receptor domain is capable of binding to a receptor with a IC50 of less than 100 nM.

### Claim 28 (depends on 26)

The bacterial cell of claim 26, wherein the moiety known to bind a receptor domain is capable of binding to a receptor with a IC50 of less than 10 nM.

### Claim 29 (depends on 26)

The bacterial cell of claim 26, wherein the moiety known to bind a receptor domain is capable of binding to a receptor with a IC50 of less than 1 nM.

### Claim 30

A method for identifying a molecule that binds a known target receptor in a bacterial cell from a pool of candidate molecules, comprising:
(a) forming a dimeric molecule by covalently bonding each molecule in the pool of candidate molecules to a ligand capable of selectively binding to a receptor;
(b) introducing the dimeric molecule into a bacterial cell culture comprising bacterial cells that express
a first fusion protein which comprises the known target receptor domain against which the candidate molecule is screened,
a second fusion protein which comprises the receptor domain to which the ligand selectively binds, and
a reporter gene wherein expression of the reporter gene is conditioned on the proximity of the first fusion protein to the second fusion protein;
(c) permitting the dimeric molecule to bind to the first fusion protein and to the second fusion protein, bringing the two fusion proteins into proximity so as to activate the expression of the reporter gene;
(d) selecting the bacterial cell that expresses the reporter gene; and
(e) identifying the small molecule that binds the known target receptor.

### Claim 31 (depends on 30)

The method of claim 30, wherein the steps (b)-(e) of the method are iteratively repeated in the presence of a preparation of random small molecules for competitive binding with the screening molecule so as to identify a molecule capable of competitively binding the known target receptor.

### Claim 32 (depends on 30)

The method of claim 30, wherein the dimeric molecule is obtained from a combinatorial library.

### Claim 33 (depends on 30)

The method of claim 30, wherein the dimeric molecule comprises a ligand capable of selectively binding to a receptor with a IC50 of less than 100 μM.

### Claim 34 (depends on 33)

The method of claim 33, wherein the dimeric molecule comprises a ligand capable of selectively binding to a receptor with a IC50 of less than 100 nM.

### Claim 35 (depends on 34)

The method of claim 34, wherein the dimeric molecule comprises a ligand capable of selectively binding to a receptor with a IC50 of less than 1 nM.

### Claim 36 (depends on 30)

The method of claim 30, wherein the dimeric molecule comprises a methotrexate moiety, FK506 moiety, an FK506 analog, a tetracycline moiety, or a cephem moiety.

### Claim 37 (depends on 30)

The method of claim 30, wherein the dimeric molecule comprises a methotrexate moiety.

### Claim 38 (depends on 30)

The method of claim 30, wherein the dimeric molecule comprises an FK506 analog.

### Claim 39 (depends on 38)

The method of claim 38, wherein the FK506 analog has the structure:
11

### Claim 40 (depends on 30)

The method of claim 30, wherein the first fusion protein further comprises a DNA binding domain, and the second fusion protein further comprises a transcription activation domain.

### Claim 41 (depends on 30)

The method of claim 30, wherein the first fusion protein further comprises a transcription activation domain, and the second fusion protein further comprises a DNA binding domain.

### Claim 42 (depends on 40, 41)

The method of claim 40 or 41, wherein the transcription activation domain is αNTD.

### Claim 43 (depends on 40, 41)

The method of claim 40 or 41, wherein the DNA-binding domain is λcI, AraC, LexA, Gal4, or zinc fingers.

### Claim 44 (depends on 30)

The method of claim 30, wherein the first or the second fusion protein comprises a receptor domain of dihydrofolate reductase (“DHFR”), glucocorticoid receptor, FKBP12, FKBP mutants, tetracycline repressor, or a penicillin binding protein.

### Claim 45 (depends on 44)

The method of claim 44, wherein the DHFR is the E. coli DHFR (“eDHFR”).

### Claim 46 (depends on 30)

The method of claim 30, wherein the first fusion protein is DHFR-λcI or FKBP12-λcI.

### Claim 47 (depends on 30)

The method of claim 30, wherein the second fusion protein is DHFR-αNTD or FKBP12-αNTD.

### Claim 48 (depends on 30)

The method of claim 30, wherein the reporter gene is Lac Z, araBAD, aadA, his3, β-lactamase, GFP, luciferase, TetR, KanR, Cm.

### Claim 49 (depends on 48)

The method of claim 48, wherein the reporter gene is Lac Z.

### Claim 50

A method for identifying an unknown target receptor to which a known molecule is capable of binding in a bacterial cell, comprising:
(a) providing a dimeric molecule having a first ligand which has a specificity for the unknown target receptor covalently bonded to a second ligand capable of selectively binding to a receptor;
(b) introducing the dimeric molecule into a bacterial cell which expresses
a first fusion protein which comprises the unknown target receptor domain,
a second fusion protein which comprises the receptor domain to which the second ligand selectively binds, and
a reporter gene wherein expression of the reporter gene is conditioned on the proximity of the first fusion protein to the second fusion protein;
(c) permitting the dimeric molecule to bind to the first fusion protein and to the second fusion protein so as to activate the expression of the reporter gene;
(d) selecting which bacterial cell expresses the unknown target receptor; and
(e) identifying the unknown target receptor.

### Claim 51 (depends on 50)

The method of claim 50, wherein the unknown target receptor is encoded by a DNA from the group consisting of genomicDNA, cDNA and syntheticDNA.

### Claim 52 (depends on 50)

The method of claim 50, wherein the steps (b)-(e) of the method are iteratively repeated so as to identify the unkown target receptor.

### Claim 53 (depends on 50)

The method of claim 50, wherein the dimeric molecule comprises a ligand capable of selectively binding to a receptor with a IC50 of less than 100 μM.

### Claim 54 (depends on 50)

The method of claim 50, wherein the dimeric molecule comprises a ligand capable of selectively binding to a receptor with a IC50 of less than 100 nM.

### Claim 55 (depends on 50)

The method of claim 50, wherein the dimeric molecule comprises a ligand capable of selectively binding to a receptor with a IC50 of less than 1 nM.

### Claim 56 (depends on 50)

The method of claim 50, wherein the dimeric molecule comprises a methotrexate moiety, FK506 moiety, an FK506 analog, a teracycline moiety, or a cephem moiety.

### Claim 57 (depends on 50)

The method of claim 50, wherein the dimeric molecule comprises a methotrexate moiety.

### Claim 58 (depends on 50)

The method of claim 50, wherein the dimeric molecule comprises an FK506 analog.

### Claim 59 (depends on 58)

The method of claim 58, wherein the FK506 analog has the structure:
12

### Claim 60 (depends on 50)

The method of claim 50, wherein the first fusion protein further comprises a DNA binding domain, and the second fusion protein further comprises a transcription activation domain.

### Claim 61 (depends on 50)

The method of claim 50, wherein the first fusion protein further comprises a transcription activation domain, and the second fusion protein further comprises a DNA binding domain.

### Claim 62 (depends on 60, 61)

The method of claim 60 or 61, wherein the transcription activation domain is αNTD.

### Claim 63 (depends on 60, 61)

The method of claim 60 or 61, wherein the DNA-binding domain is λcI, AraC, LexA, Gal4, or zinc fingers.

### Claim 64 (depends on 50)

The method of claim 50, wherein the first or the second fusion protein comprises a receptor domain of dihydrofolate reductase (“DHFR”), glucocorticoid receptor, FKBP12, FKBP mutants, tetracycline repressor, or a penicillin binding protein.

### Claim 65 (depends on 64)

The method of claim 64, wherein the DHFR is the E. coli DHFR (“eDHFR”).

### Claim 66 (depends on 50)

The method of claim 50, wherein the first fusion protein is DHFR-λcI or FKBP12-λcI.

### Claim 67 (depends on 50)

The method of claim 50, wherein the second fusion protein is DHFR-αNTD or FKBP12-αNTD.

### Claim 68 (depends on 50)

The method of claim 50, wherein the reporter gene is Lac Z, araBAD, aadA, his3, β-lactamase, GFP, luciferase, TetR, KanR, Cm.

### Claim 69 (depends on 68)

The method of claim 68, wherein the reporter gene is Lac Z.

### Claim 70

A kit for identifying a molecule that binds to a known target in a bacterial cell from a pool of candidate molecules, comprising
(a) a host bacterial cell containing a reporter gene that is expressed only when bound to a DNA-binding domain and when in the proximity of a transcription activation domain;
(b) a first vector containing a promoter that functions in the host bacterial cell and a DNA encoding a DNA-binding domain;
(c) a second vector containing a promoter that functions in the host bacterial cell and a DNA encoding a transcription activation domain;
(d) a dimeric small molecule which comprises a moiety that binds to a known receptor domain covalently linked to a candidate molecule;
(e) a means for inserting into the first vector or the second vector a DNA encoding the known receptor domain in such a manner that the known receptor domain and an expression product of the first or second vector are expressed as a fusion protein;
(f) a means for inserting into the first vector or the second vector a DNA encoding the known target receptor in such a manner that the known target receptor and an expression product of the first or second vector are expressed as a fusion protein; and
(g) a means for transfecting the host cell with the first vector, and the second vector,
wherein binding of the dimeric small molecule to the known target receptor results in a measurably greater expression of the reporter gene then in the absence of such binding.

### Claim 71

A kit for identifying an unknown target receptor to which a molecule is capable of binding in a bacterial cell, comprising
(a) a host bacterial cell containing a reporter gene that is expressed only when bound to a DNA-binding domain and when in the proximity of a transcription activation domain;
(b) a first vector containing a promoter that functions in the host bacterial cell and a DNA encoding a DNA-binding domain;
(c) a second vector containing a promoter that functions in the host bacterial cell and a DNA encoding a transcription activation domain;
(d) a dimeric small molecule which comprises a moiety that binds a known receptor domain covalently linked to a moiety against which the unknown target is to be screened for binding;
(e) a means for inserting into the first vector or the second vector a DNA encoding the known receptor domain in such a manner that the known receptor domain and an expression product of the first or second vector are expressed as a fusion protein;
(f) a means for inserting into the first vector or the second vector a DNA encoding the unknown target receptor in such a manner that the unknown target receptor and an expression product of the first or second vector are expressed as a fusion protein; and
(g) a means for transfecting the host cell with the first vector, and the second vector,
wherein binding of the dimeric small molecule to the unknown target receptor results in a measurably greater expression of the reporter gene then in the absence of such binding.

### Claim 72 (depends on 30)

A process for screening a chemical library for a molecule that binds a known target receptor, comprising providing a chemical library, providing a bacterial cell that expresses the known target receptor as a part of a fusion protein, and identifying the molecule that binds the known target receptor in the bacterial cell by the method of claim 30.

### Claim 73 (depends on 72)

A molecule identified by the method of claim 72, wherein the molecule was not previously known to bind the known target receptor.

### Claim 74 (depends on 50)

A process for screening a cDNA library for a nucleic acid that encodes a receptor to which a known molecule binds, comprising providing a cDNA library, providing a dimeric molecule having two ligands, of which one ligand is the known molecule, and identifying the nucleic acid that encodes the receptor to which the known molecule binds by the method of claim 50.

### Claim 75 (depends on 74)

An isolated nucleic acid identified by the process of claim 74, wherein the isolated nucleic acid was not previously known to encode a receptor to which the known molecule binds.

### Claim 76 (depends on 75)

The isolated nucleic acid of claim 75, wherein the isolated nucleic acid encodes an enzyme or a portion thereof.

### Claim 77

A transgenic bacterial cell comprising
(a) a dimeric small molecule which comprises a methotrexate moiety covalently linked to a moiety capable of binding a receptor domain;
(b) nucleotide sequences which upon transcription encode
i) a first fusion protein comprising a DHFR domain and a first fragment of an enzyme, and
ii) a second fusion protein comprising the receptor domain and a second fragment of the enzyme,
wherein activity of the enzyme is conditioned on the proximity of the first fragment of the enzyme to the second fragment of the enzyme.

### Claim 78 (depends on 77)

The bacterial cell of claim 77, wherein the moiety capable of binding the receptor domain is capable of binding with a IC50 of less than 100 μM.

### Claim 79 (depends on 77)

The bacterial cell of claim 77, wherein the moiety capable of binding the receptor domain is capable of binding with a IC50 of less than 100 nM.

### Claim 80 (depends on 77)

The bacterial cell of claim 77, wherein the moiety capable of binding the receptor domain is capable of binding with a IC50 of less than 1 nM.

### Claim 81

A method for identifying a molecule that binds a known target receptor in a bacterial cell from a pool of candidate molecules, comprising:
(a) forming a dimeric molecule by covalently bonding each molecule in the pool of candidate molecules to a methotrexate moiety;
(b) introducing the dimeric molecule into a bacterial cell culture comprising bacterial cells that express
a first fusion protein which comprises the known target receptor domain against which the candidate molecule is screened, and a first fragment of an enzyme, and
a second fusion protein which comprises a DHFR receptor domain and a second fragment of the enzyme;
(c) permitting the dimeric molecule to bind to the first fusion protein and to the second fusion protein, bringing the first fragment and the second fragment of the enzyme in to proximity so as to reconstitute the activity of the enzyme;
(d) selecting the bacterial cell that exhibits the activity of the enzyme; and
(e) identifying the small molecule that binds the known target receptor.

### Claim 82

A method for identifying an unknown target receptor to which a known molecule is capable of binding in a bacterial cell, comprising:
(a) providing a dimeric molecule having a first ligand which has a specificity for the unknown target receptor covalently bonded to a methotrexate moiety;
(b) introducing the dimeric molecule into a bacterial cell which expresses
a first fusion protein which comprises the unknown target receptor domain, and a first fragment of an enzyme, and
a second fusion protein which comprises a DHFR receptor domain and a second fragment of the enzyme;
(c) permitting the dimeric molecule to bind to the first fusion protein and to the second fusion protein, bringing the first fragment and the second fragment of the enzyme in to proximity so as to reconstitute the activity of the enzyme;
(d) selecting the bacterial cell that exhibits the activity of the enzyme; and
(e) identifying the unknown target receptor.
